Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000929638-25-001925
Filing Date
2025-05-15
Accepted
2025-05-15 17:20:50
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5841
  Complete submission text file 0000929638-25-001925.txt   7415
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Subject) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91717 | Film No.: 25955867
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O PRELUDE THERAPEUTICS INCORPORATED 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address
Vaddi Krishna (Filed by) CIK: 0001824633 (see all company filings)

Type: SCHEDULE 13G/A